ClinicalTrials.gg
TerminatedNCT04255862Updated Apr 10, 2025Results posted

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

A Phase 1 interventional study of Bimekizumab in Healthy Study Participants, sponsored by UCB Biopharma SRL. Terminated at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Why this study was terminated
Study recruitment temporarily halted due to difficulties executing the study under the COVID-19 pandemic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study is to compare the pharmacokinetics (PK) of bimekizumab when administered subcutaneously (sc) as 1x2 mL versus 2x1 mL, using a bimekizumab-safety syringe presentation or bimekizumab-auto-injector presentation, in healthy study participants.

02

Conditions studied

  • Healthy Study Participants

Keywords

  • UCB4940
  • Bimekizumab
  • Bioequivalence
  • Auto-injector
  • Healthy study participants
  • Safety-syringe
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be ≥18 years and ≤65 years of age inclusive, at the time of signing the
  • Study participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, 12-lead (ECG), and laboratory tests, during the Screening Visit and on admission
  • Body weight minimum of 50 kg for male and 45 kg for female study participants and a maximum of 100 kg for all study participants, and (BMI) within the range 18 to 32 kg/m\^2 (inclusive) at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  • Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study
  • Study participant has a known to any of bimekizumab (and/or an device) as stated in this protocol
  • Study participant has cardiovascular or cerebrovascular disease, including hypertension, angina, ischemic heart disease, , stroke, peripheral arterial disease sufficient to cause symptoms, and/or requires therapy to maintain stable status
  • Study participant has an active infection or history of infections as follows:

    1. Any active infection (except common cold) within 14 days prior to the Screening Visit
    2. A serious infection, defined as requiring hospitalization or iv anti-infectives within 2 months prior to the Screening Visit
    3. A history of opportunistic, recurrent, or chronic infections that, in the opinion of the Investigator, might cause this study to be detrimental to the study participant. Opportunistic infections are infections caused by uncommon pathogens (eg, pneumocystis jirovecii, cryptococcosis) or unusually severe infections caused by common pathogens (eg, cytomegalovirus, herpes zoster)
  • Study participant has a history of a positive tuberculosis (TB) test or evidence of possible TB or latent TB infection at the Screening Visit
  • Study participant has concurrent acute or chronic viral or C or (HIV) infection. Study participants who have evidence of, or tested positive for hepatitis B or are excluded
  • Study participant has 12-lead with changes considered to be (eg, corrected using Fridericia's formula [QTcF] >450 ms, bundle branch block, or evidence of myocardial ischemia) at the Screening Visit or on Day -1
  • Study participant has active neoplastic disease or history of neoplastic disease within 5 years of the Screening Visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care)
  • Study participants receiving any live (includes attenuated) vaccination within the 8 weeks prior to the Screening Visit (eg, inactivated influenza and pneumococcal vaccines are allowed but nasal influenza vaccination is not permitted). are not allowed during the study or for 20 weeks after the dose of the investigational medicinal product (IMP)
  • Study participant has previously participated in this study or the study participant has previously been assigned to treatment in a study of the medication under investigation in this study
  • Study participant has participated in another study of an IMP (and/or an investigational device) within the previous 90 days or 5 half-lives, whichever is longer, prior to IMP administration
  • Study participant has made a blood donation of a blood loss of more than 400 mL of blood or blood products within 90 days prior to admission (Day -1) or plans to donate blood during the study
  • Study participant has a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in real-time reverse transcriptase polymerase chain reaction (RT-PCR) on the admission sample
  • Study participant has clinical signs and symptoms consistent with coronavirus disease 2019 (COVID-19), eg fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the previous 14 days prior to Screening or on admission
  • Study participant who had severe course of COVID-19 (ie, hospitalization, extracorporal membrane oxygenation, mechanically ventilated)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Test 1

    Study participants randomized to this arm will receive bimekizumab administered subcutaneously with bimekizumab-safety syringe-2 mL presentation (test 1).

    Drug: Bimekizumab

  • Other
    Reference 1

    Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-safety syringe-1 mL presentation (reference 1).

    Drug: Bimekizumab

  • Experimental
    Test 2

    Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-2 mL presentation (test 2).

    Drug: Bimekizumab

  • Other
    Reference 2

    Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-1 mL (reference 2).

    Drug: Bimekizumab

Interventions

  • Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.

    Also known as: UCB4940, BKZ

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)

    AUC is the area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to infinity.

    Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)

  2. Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)

    AUC0-t is the area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to the last observed quantifiable concentration.

    Time frame: From Baseline (Day 1 predose) at predefined time points to the last quantifiable concentration (Day 140)

  3. Maximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)

    Cmax is the maximum observed plasma concentration.

    Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)

Secondary outcomes

  1. Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as any event not present prior to the administration of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to study treatment.

    Time frame: From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)

  2. Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up

    A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: a. Results in death, b. Is life-threatening, c. Requires inpatient hospitalization or prolongation of existing hospitalization, d. Results in persistent disability/incapacity, e. Is a congenital anomaly/ birth defect, f. Other important medical events which based on appropriate medical judgment, jeopardized the study participant and required medical or surgical intervention to prevent any of the above.

    Time frame: From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)

  3. Apparent Terminal Half-life (t1/2)

    Apparent terminal half-life, reported in units of days, as determined via simple linear regression (slope=-lambdaz) of natural log (ln) concentration versus time for data points in the terminal phase of the concentration-time curve. t1/2 is calculated as ln2/lambdaz.

    Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)

  4. Time of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)

    tmax is the time to reach maximum plasma concentration.

    Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)

07

Results

Posted Apr 10, 2025

Participant flow

The study started to enroll study participants in February 2020 and concluded in April 2021.

Participant flow — Overall Study
MilestoneBimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Started18181718
Completed18181718
Not completed0000

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)

AUC is the area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to infinity.

Time frame:
From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Reported as:
Geometric mean · days*micrograms/milliliter (days*ug/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)
days*micrograms/milliliter (days*ug/mL)Bimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)1665 ± 34.21610 ± 31.31560 ± 19.11357 ± 35.5
Statistical analysis
  • Bimekizumab-SS-2mL (Test 1) vs Bimekizumab-SS-2x1mL (Reference 1) · Geometric mean ratio: 103.4 · 90% CI 86.4 to 123.8
  • Bimekizumab-AI-2mL (Test 2) vs Bimekizumab-AI-2x1mL (Reference 2) · Geometric mean ratio: 115.0 · 90% CI 97.9 to 135.0
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)

AUC0-t is the area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to the last observed quantifiable concentration.

Time frame:
From Baseline (Day 1 predose) at predefined time points to the last quantifiable concentration (Day 140)
Reported as:
Geometric mean · days*ug/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)
days*ug/mLBimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)1551 ± 31.41509 ± 29.21469 ± 17.51296 ± 33.7
Statistical analysis
  • Bimekizumab-SS-2mL (Test 1) vs Bimekizumab-SS-2x1mL (Reference 1) · Geometric mean ratio: 102.8 · 90% CI 87.0 to 121.5
  • Bimekizumab-AI-2mL (Test 2) vs Bimekizumab-AI-2x1mL (Reference 2) · Geometric mean ratio: 113.4 · 90% CI 97.4 to 131.9
PrimaryMaximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)

Cmax is the maximum observed plasma concentration.

Time frame:
From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Reported as:
Geometric mean · ug/mL
Maximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)
ug/mLBimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Maximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)43.56 ± 26.841.90 ± 23.942.23 ± 20.336.94 ± 28.2
Statistical analysis
  • Bimekizumab-SS-2mL (Test 1) vs Bimekizumab-SS-2x1mL (Reference 1) · Geometric mean ratio: 104.0 · 90% CI 90.3 to 119.7
  • Bimekizumab-AI-2mL (Test 2) vs Bimekizumab-AI-2x1mL (Reference 2) · Geometric mean ratio: 114.3 · 90% CI 99.5 to 131.4
SecondaryPercentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as any event not present prior to the administration of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to study treatment.

Time frame:
From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up
percentage of participantsBimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up66.744.470.638.9
SecondaryPercentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up

A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: a. Results in death, b. Is life-threatening, c. Requires inpatient hospitalization or prolongation of existing hospitalization, d. Results in persistent disability/incapacity, e. Is a congenital anomaly/ birth defect, f. Other important medical events which based on appropriate medical judgment, jeopardized the study participant and required medical or surgical intervention to prevent any of the above.

Time frame:
From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up
percentage of participantsBimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up0000
SecondaryApparent Terminal Half-life (t1/2)

Apparent terminal half-life, reported in units of days, as determined via simple linear regression (slope=-lambdaz) of natural log (ln) concentration versus time for data points in the terminal phase of the concentration-time curve. t1/2 is calculated as ln2/lambdaz.

Time frame:
From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Reported as:
Geometric mean · days
Apparent Terminal Half-life (t1/2)
daysBimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Apparent Terminal Half-life (t1/2)28.21 ± 17.327.24 ± 16.825.73 ± 27.822.84 ± 28.7
SecondaryTime of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)

tmax is the time to reach maximum plasma concentration.

Time frame:
From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Reported as:
Median · days
Time of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)
daysBimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Time of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)6.981 (2.99 to 15.0)6.988 (2.92 to 12.0)6.943 (3.98 to 12.0)6.972 (3.00 to 8.98)

Adverse events

Collected over From Baseline (Day 1) to end of Safety Follow-Up Visit (up to Day 140). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimekizumab-SS-2mL (Test 1)0/18 (0%)0/18 (0%)12/18 (66.7%)
Bimekizumab-SS-2x1mL (Reference 1)0/18 (0%)0/18 (0%)8/18 (44.4%)
Bimekizumab-AI-2mL (Test 2)0/17 (0%)0/17 (0%)12/17 (70.6%)
Bimekizumab-AI-2x1mL (Reference 2)0/18 (0%)0/18 (0%)7/18 (38.9%)
Most frequent other events
Showing 10 of 44
Most frequent other events
EventBimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)
Back painMusculoskeletal and connective tissue disorders1/182/184/170/18
HeadacheNervous system disorders4/184/183/171/18
Injection site haematomaGeneral disorders1/180/180/173/18
Dry mouthGastrointestinal disorders0/181/182/170/18
NauseaGastrointestinal disorders0/182/180/170/18
Oral herpesInfections and infestations2/181/180/170/18
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/180/181/172/18
Dry skinSkin and subcutaneous tissue disorders2/180/180/170/18
FlatulenceGastrointestinal disorders0/180/181/170/18
Gingival discomfortGastrointestinal disorders0/180/181/170/18

Baseline characteristics

Baseline Characteristics refer to the Full Analysis Set (FAS) which consisted of all randomized study participants who received full or partial investigational medicinal product (IMP) according to the treatment the study participants actually received.

Age, Categorical
Age, Categorical(Participants)Bimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)Total
<=18 years00000
Between 18 and 65 years1717161666
>=65 years11125
Age, Continuous
Age, Continuous(years)Bimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)Total
Mean52.6 ± 12.851.1 ± 15.846.8 ± 15.746.7 ± 15.749.3 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Bimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)Total
Female1213131351
Male654520
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)Total
White1717171869
Other/Black01001
Other/Caucasian10001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab-SS-2mL (Test 1)Bimekizumab-SS-2x1mL (Reference 1)Bimekizumab-AI-2mL (Test 2)Bimekizumab-AI-2x1mL (Reference 2)Total
Not Hispanic or Latino1818171871
08

Study locations

1 site
  • Up0068 001
    Berlin, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data from Phase 1 trials in Healthy Volunteers is outside of UCB's data sharing policy and is unavailable for sharing.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Apr 2021, 14 months.

Results were first posted in Apr 2025, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2020
First posted
Feb 5, 2020
StartActual
Feb 12, 2020
Primary completionActual
Apr 26, 2021
CompletionActual
Apr 26, 2021
Results first posted
Apr 10, 2025
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04255862
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Feb 12, 2020
Primary completion
Apr 26, 2021
Completion
Apr 26, 2021
Results posted
Apr 10, 2025
Last update
Apr 10, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion